Member Info for mulledwine

http://www.investegate.co.uk/centaur-media-plc-(cau)/rns/interim-management-statement/201211140700110384R/

Financial position SIG has maintained its strong financial position and remains on track to meet its target of c.1x leverage at the year end. Outlook As the Group anticipated at the beginning of the year, market volumes have declined slightly in 2012. Against this trading background SIG has focused on improving business performance, as set out in its pillars of profit recovery, and outperforming its markets. Having benefited from these management initiatives, SIG remains on track to meet its expectations, subject, as usual, to any exceptional adverse weather conditions in the remainder of the year. Conference call There will be a conference call for analysts and investors at 8.00am today to discuss the statement. The dial-in details are: +44 (0)20 3140 0668, PIN: 844492#.

Growth Initiatives Three bolt-on acquisitions have been completed so far in the second half of the year. They were: · a single site specialist insulation distribution business in Toulouse, France, the gross assets of which were €2.7m as at 31 March 2012; · a Heating, Ventilation and Air Conditioning (HVAC) distribution business in Charleroi, Belgium, the gross assets of which were €0.4m on completion; and · a roofing branch in Kings Lynn, UK, which was bought out of administration for a de minimis figure. The Group is continuing to pursue a pipeline of small infill acquisition opportunities within its core markets. SIG expects total acquisition expenditure in 2012 to be c.£8m. In addition SIG has opened 6 new branches in H2 to date, bringing the total to 21 for the year.

Trading summary Trading has been in line with expectations, with sales per day from continuing operations for the ten months to the end of October flat on a constant currency basis. Sterling sales per day fell by c.4% compared to prior year due to exchange rate movements. Year to date sales per day in Mainland Europe increased by c.2% in constant currency, but fell by c.6% in Sterling. Benelux and France exhibited the strongest progress, with Germany marginally down. In the UK & Ireland sales per day from continuing operations fell by c.2% in constant currency, with the UK down by c.1%. Following some improvement in constant currency sales per day in Q3 compared to Q2 on a year-on-year basis, October was slightly negative, meaning that July to October was flat compared with prior year. Overall gross margin remains ahead of the same period last year. SIG continues to expect that the rate of improvement for the full year will be lower than the 50bps increase reported in H1. The Group is also continuing to keep a tight control on operating costs and is on track to deliver further efficiency savings as detailed in its Interim Results.

Interim Management Statement SIG plc ("SIG" or "the Group"), a leading distributor of specialist building products in Europe, with strong positions in its core markets of insulation & energy management, interior fit out and roofing products, today issues this Interim Management Statement for the period commencing 1 July 2012. As detailed in a separate announcement released today, Chris Davies will leave SIG in March 2013 after 19 years' service to focus on non-executive roles. He will be succeeded by Stuart Mitchell, who joins SIG from Wilkinson Hardware Stores.

http://www.investegate.co.uk/sig-plc-(shi)/rns/interim-management-statement/201211140700130418R/

Outlook Economic growth in the western world remains anaemic at best. Furthermore, growth in China showed signs of further slowdown in quarter 3. Although there has been a recent rally in European Bond markets following the President of the European Central Bank Mario Draghi's pledge to `do whatever it takes' to preserve the Euro, this in itself does not resolve the fundamental issues facing Europe. Against this backdrop, the Company's investment strategy remains unaltered. As the Board has emphasised in the past, the concentrated nature of the portfolio may from time to time give rise to material short term under-performance against benchmark. However, from a medium to longer term perspective, the Company's investment portfolio has been constructed with stocks which should be resilient in difficult times, whilst still providing potential upside in more positive market environments.

Retail Distribution Review (`RDR') RDR comes into effect on 31 December 2012 and will have significant implications in respect of how financial advice is provided, retail fund platforms operate and financial products are distributed. Many commentators have suggested that the abolition of commission under RDR should result in more retail demand for investment trusts. The likely beneficiaries of this demand, should it materialise, would be the larger investment trusts, such as The Edinburgh Investment Trust plc, which have good levels of liquidity in their own shares and can demonstrate a strong investment track record, a clear investment strategy and a compelling brand. The Board continues to monitor developments on RDR closely as they evolve to ensure that the Company is positioned appropriately to benefit in the new environment of 2013 and thereafter.

Gearing The Company continues to have long-term debt amounting to £200 million. This is all deployed in the market for investment purposes. At the end of the period the net gearing level was 20.0% compared to 20.3% at 31st March 2012. Dividend Income from the portfolio for the 6 months to 30 September 2012 was £26.8m (2011: £26.0m), with a corresponding increase in return per share from 11p to 11.3p. The Board has declared an unchanged first interim dividend of 5.0 pence per share and this will be paid on 30 November 2012 to shareholders on the register on the 16 November 2012.

KeywordCompanyEPIC/TIDMSEDOL/ISINNews Price Announcements Fundamentals News Article RSS Edinburgh Inv. Trust (EDIN) Add to Alerts list Print Mail a friend Annual reports Wednesday 14 November, 2012 Edinburgh Inv. Trust Half-yearly Report The Edinburgh Investment Trust plc Half-Yearly Financial Report Six months to 30 September 2012 Financial Information and Performance Statistics The Edinburgh Investment Trust plc (the `Company') is a UK investment trust listed on the London Stock Exchange, which invests primarily in UK securities. Investment Objective of the Company The Company invests primarily in UK securities with the long term objective of achieving: 1. an increase of the Net Asset Value per share by more than the growth in the FTSE All-Share Index; and 2. growth in dividends per share by more than the rate of UK inflation. Performance Statistics At At 30 September 31 March % 2012 2012 Change Capital Return Net asset value (`NAV'):   - debt at par 506.36p 502.03p +0.9   - debt at market value 480.11p 478.30p +0.4 FTSE All-Share Index 2998.86 3002.78 -0.1 Share price 517.0p 497.6p +3.9 (Premium)/discount:   - debt at par (2.1)% 0.9%   - debt at market value (7.7)% (

http://www.investegate.co.uk/edinburgh-inv.-trust-(edin)/prn/halfyearly-report/20121114070000P1FDD/

Healthcare division Demand for our liquid based cytology (`LBC') service, which supports 50% of the Cervical Cancer Screening Programme for England and Wales, continues to be strong. The roll out of the BD FocalPoint™ automated imaging platform for cervical cancer screening has driven growth in the Cytology business. In the short term, we expect a number of additional NHS Trusts to adopt this imaging technology. Molecular diagnostic testing continues to gain clinical relevance and importance in the NHS, especially gene-based companion diagnostic testing. Companion diagnostic testing provides information about how a patient might respond to a particular drug therapy. One of the most widely utilised tests is the K-RAS gene test for colorectal cancer and demand in the period was up more than 70% compared with the same period last year. Source BioScience is one of only a few accredited laboratories in Europe with the capability to deliver this type of complex diagnostic testing and the growing demand strengthens the Group's commercial advantage. To conclude, the Group has made good progress in the period and we expect full year profits to be in line with market expectations.

LifeSciences division The Overnight Service for DNA sequencing has enabled the Group to further increase its share of the UK market. Sequencing volumes during Q3 were 27% greater than the same period last year and 46% up on a year to date basis. This enhanced service has also enabled the Group to win sequencing tenders from the Universities of Warwick and Newcastle. In July we announced an extended next generation sequencing service using the new Illumina MiSeq™ platform. This platform addresses the "middle ground" between the Group's existing sequencing technologies and has already attracted customers from both the life science research and healthcare communities. GenomeCube®, our proprietary search engine and bioinformatics tool for our clone and antibody portfolio, has enabled the appointment of additional distributors, extending the global reach of our products business. In August we announced the appointment of a third distributor in the important South East Asia market, Benebiosis of South Korea, and in the period we appointed a fourth distributor in the region, Michrom of Malaysia. During the period we further enhanced our network in Europe with additional distributors appointed in Turkey, Italy and Poland.

INTERIM MANAGEMENT STATEMENT Source BioScience plc (LSE: SBS), the international diagnostics and genetic analysis business serving the healthcare and research markets today publishes its Interim Management Statement for the period from 1 July 2012 to 14 November 2012. Unless otherwise stated, the financial information referenced below refers to the three months ended 30 September 2012, and the corresponding period last year, this being the latest practicable date to which financial information has been prepared. Overall business performance The third quarter of 2012 has been another period of sustained growth and development for Source BioScience with increased revenue in both the LifeSciences and Healthcare divisions, compared with the same period last year. This performance has been underpinned by growth in the Cytology business, driven by the adoption of automated imaging for cervical cancer screening, coupled with increasing market share for DNA sequencing in the UK. The Group remains in a robust financial position with £2.0 million cash at the end of September 2012 (30 June 2012: £1.8 million). Overall performance for the year to date is in line with management's expectations, representing a continuation of the strong business performance achieved last year. We expect full year profits to be in line with market expectations.

http://www.investegate.co.uk/source-bioscience-(sbs)/prn/interim-management-statement/20121114070000PAB9F/

Simon Richards, Chairman, commented: "We are pleased with the continued growth in the business in the first half of the year. Both business segments showed significant sales growth and this bodes well for the medium term prospects for the business. The balance sheet has continued to get stronger and we are delighted to declare a 25% increase in the dividend, which remains well covered by earnings, whilst enabling us to retain a significant strategic cash reserve." "We continue to invest in new products, which we believe will contribute to the long term success of the group and are particularly encouraged by our new food safety product."

HALF YEARLY REPORT FOR THE SIX MONTHS TO 30 SEPTEMBER 2012 Red24 plc ("red 24" or the "Group") is pleased to announce its unaudited results for the half year to 30 September 2012. Highlights: · Revenue increased by 15.4% to £3.3 million (H1 2011: £2.9 million) · Profit before tax of £440k (H1 2011: £412k) · EPS of 0.75p (H1 2011: 0.73p) · Dividend increased by 25% to 0.40p (2011: 0.32p) - over four times covered by 2011 earnings · HSBC contract renewed for further year · Food safety product revenues exceed target

http://www.investegate.co.uk/red24-plc-(redt)/rns/half-yearly-report/201211140700100378R/

N+1 Singer maintained its "buy" recommendation on Trifast (TRI), the manufacturer of mechanical fastenings, with a target price of 60p, up from 58p. The broker recognises that the firm has had a good first half, with sales growing by 11% to 62.1 million pounds, boosted by last year's acquisition of Power Steel. Coupled with the leverage of Power Steel's low cost, high margin manufacturing operation the broker believes that the share price could and should increase. The shares were up by 1.875p at 44p.

Panmure Gordon has re-issued a "sell" recommendation on Cineworld (CINE) with a target price of 220p. The broker feels that the cinema operator had a particularly weak period for the 19 weeks ended 8th November 2012 as admissions fell 4.1% on last year's corresponding period. Although the broker noted the firm has had a promising start to the fourth quarter, with a strong performance from Bond film "Skyfall", it is nervous that there is not enough time for admissions to play catch up on the relative underperformance over the last quarter. The shares gained 10.25p to 249p